NewAmsterdam Pharma Company N.V. (NAMS)
(Real Time Quote from BATS)
$21.68 USD
+0.02 (0.09%)
Updated Aug 5, 2025 02:54 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, NewAmsterdam Pharma Company N.V. has a market cap of $2.43B, which represents its share price of $21.66 multiplied by its outstanding shares number of 112.27M. As a mid-cap company, NAMS's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NAMS 21.68 +0.02(0.09%)
Will NAMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Other News for NAMS
RA CAPITAL MANAGEMENT, L.P. Acquires 2,122,000 Shares in Contineum Therapeutics Inc
NewAmsterdam Pharma's Obicetrapib Shows Promise in Alzheimer's Biomarker Reduction | NAMS stock news
NewAmsterdam Pharma (NAMS) Releases Alzheimer's Biomarker Data from BROADWAY Trial
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically ...
NewAmsterdam Pharma presents data from BROADWAY trial at AAIC